Transverse Myelitis
Transverse myelitis (TM) is a neurological disorder characterized by inflammation of the spinal cord, leading to motor, sensory, and autonomic dysfunction. As a leading research service provider, our company is at the forefront of developing innovative drug and therapy options for transverse myelitis (TM).
Overview of Transverse Myelitis
Transverse myelitis (TM) is an uncommon neurological disorder distinguished by inflammation occurring within the spinal cord. It can affect individuals across various age groups, with a higher incidence observed in young adults. Although the precise cause of transverse myelitis remains elusive, it frequently follows viral or bacterial infections, autoimmune disorders, or other inflammatory conditions. The hallmark symptoms of transverse myelitis encompass the sudden onset of motor weakness, sensory disturbances, and dysfunction of the autonomic nervous system below the level of the spinal cord lesion.
Fig.1 Infectious agents as causative of transverse myelitis. (Rodríguez Y., et al., 2018)
Therapy Discovery and Development for Transverse Myelitis
Currently, the standard approach in the therapeutic of transverse myelitis (TM) involves the administration of intravenous glucocorticoids, such as methylprednisolone or dexamethasone. These drugs help alleviate inflammation and minimize further damage to the spinal cord. As our understanding of TM continues to evolve, there is growing interest in investigating immunomodulatory therapies for the effective therapeutic of this condition. Agents such as cyclophosphamide, mycophenolate, and rituximab, which modulate the immune system, have shown promising results in cases of chronic recurrent TM or resistant acute TM.
As shown below, our company is committed to providing innovative transverse myelitis therapeutic development services. If you are interested, please click on the link below to learn more.
Our Services
At our company, we offer a comprehensive range of services dedicated to the development of diagnostics and effective therapies for transverse myelitis. Our expertise encompasses preclinical research, animal models, and in vitro model development. Our preclinical research services play a pivotal role in the development of TM therapies. Through rigorous experimentation and analysis, we evaluate the efficacy, safety, and pharmacokinetics of potential drug candidates.
Immune Animal Models
The development of animal models is vital for gaining a comprehensive understanding of rare diseases such as TM. Through the utilization of myelin antigens1 immune models, specifically the MOG-specific EAE mouse model, we can simulate the immunological processes associated with TM and NMO.
We focuse on creating representative in vitro models that mimic the cellular processes underlying TM. By utilizing primary cells, cell lines, or induced pluripotent stem cells (iPSCs), we can study various aspects of TM pathogenesis, including immune cell activation, inflammation, and the breakdown of the blood-spinal cord barrier.
Our service focuses on creating spinal cord organoids that recapitulate the cellular diversity and architecture of the spinal cord. By introducing inflammatory stimuli or immune cells into the organoids, we can simulate the immune response and assess its impact on myelin integrity and neuronal function.
By adhering to the highest scientific standards, we ensure that our findings are robust and reliable. Beyond the wide range of services and models mentioned previously, our expertise extends to crafting bespoke solutions and designing disease models that are perfectly tailored to your individual requirements. We take great pride in our ability to adapt and customize our offerings to meet the unique needs of each client. If our comprehensive range of services has piqued your interest, we wholeheartedly encourage you to contact us without any hesitation.
References
- Rodríguez Yhojan, et al. "Guillain–Barré syndrome, transverse myelitis and infectious diseases." Cellular & molecular immunology 15.6 (2018): 547-562.
- Lim Peter AC. "Transverse myelitis." Essentials of physical medicine and rehabilitation (2020): 952.